Seattle Genetics is on the Cruelty Free Investing list for exploiting animals because the company does animal testing in research and development of some of their therapies.
“Seattle Genetics demonstrated activity of SGN-40 in multiple preclinical models of hematologic malignancies. The product candidate was well tolerated in animal models, with doses as low as 0.4 milligrams per kilogram significantly increasing survival in xenograft models.”
Seattle Genetics, Inc. engages in the development and commercialization of monoclonal antibody-based therapies for cancer. Its product ADCETRIS or brentuximab vedotin has been approved by both U.S. Food and Drug Association and Health Canada in U.S. and Canada respectively. [Source: MarketWatch]
Company Website: http://www.seattlegenetics.com/